POMDOCTOR LIMITED Announces First Half of Fiscal 2025 Unaudited Financial Results
Rhea-AI Summary
Pomdoctor (NASDAQ: POM) reported unaudited results for the six months ended June 30, 2025. Net revenue rose 16.2% to RMB174.5 million (US$24.4 million), driven by an 83.2% increase in online-pharmacy/Internet-hospital sales. Gross profit grew 16.3% to RMB28.3 million (US$4.0 million) with a stable gross margin of 16.2%. The company recorded a net loss of RMB19.9 million (US$2.8 million) and cash and cash equivalents were RMB5.7 million as of June 30, 2025. Pomdoctor completed its October 2025 IPO, raising gross proceeds of US$23,000,016.
Positive
- Net revenue +16.2% to RMB174.5 million
- Online-pharmacy/Internet hospital revenue +83.2%
- Gross profit +16.3% to RMB28.3 million
- Completed IPO raising US$23,000,016 gross proceeds
Negative
- Net loss widened to RMB19.9 million
- Net loss per share rose to RMB11.45
- Cash and cash equivalents low at RMB5.7 million
- Net cash used in operations increased to RMB15.0 million
News Market Reaction
On the day this news was published, POM gained 5.36%, reflecting a notable positive market reaction. Argus tracked a peak move of +12.1% during that session. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $33M to the company's valuation, bringing the market cap to $656M at that time. Trading volume was elevated at 2.7x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
No peers appeared in the momentum scanner and no same-day peer headlines were recorded, indicating the sharp move and elevated volume were stock-specific rather than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 03 | Earnings update | Neutral | +5.4% | Reported H1 FY2025 revenue growth with continued net loss and low cash. |
| Oct 10 | Over-allotment closing | Positive | +1.1% | Underwriter fully exercised over-allotment option, lifting total IPO proceeds. |
| Oct 09 | IPO completion | Positive | +18.4% | Initial public offering of ADSs on Nasdaq generated new capital for the company. |
Across the last three news events (IPO, over-allotment, and this earnings report), the stock showed positive next-day price reactions, suggesting a pattern of favorable responses to corporate announcements.
Over recent months, Pomdoctor listed on Nasdaq via an IPO on Oct 9, 2025, selling 5,000,004 ADSs at $4.00 and later adding 750,000 ADSs on full over-allotment exercise, for total gross proceeds of $23,000,016. These offerings saw price gains of 18.36% and 1.15% over the following day. The current H1 FY2025 report shows net revenues of RMB174.5M and gross profit of RMB28.3M, with a reported 24-hour reaction of 5.36% higher, extending the pattern of positive responses.
Market Pulse Summary
The stock moved +5.4% in the session following this news. A strong positive reaction aligns with the pattern of upbeat responses to Pomdoctor’s prior IPO-related announcements, which saw next-day gains of up to 18.36%. The H1 FY2025 release combined 16.2% net revenue growth with a higher net loss of RMB19.9M and cash of RMB5.7M, so sustainability of any sharp move would depend on future profitability and cash-flow trends, as well as how investors weigh rapid Internet hospital expansion against ongoing operating losses.
Key Terms
internet hospital technical
online pharmacy technical
initial public offering financial
ads financial
over-allotment option financial
AI-generated analysis. Not financial advice.
Mr. Zhenyang Shi, Chairman and Chief Executive Officer of Pomdoctor, commented: "The first half of fiscal year 2025 reflected our deliberate and disciplined efforts to balance business expansion with operational rigor. Despite a challenging macroeconomic environment and intensified market competition, we strived to strengthen our market coverage and penetration, while optimizing and diversifying our revenue streams through the vigorous promotion of our internet-hospital services and online sales. During the period, we continued to solidify our partner-doctor pool by offering higher service fees, and at the same time meaningfully enhanced our collaboration with pharmaceutical manufacturers to drive online sales and adapt to
At the same time, we maintained strict cost controls and operational discipline, sustaining a stable gross profit margin of
Notably, our successful initial public offering (IPO) in October provided us with additional capital resources and expanded opportunities for future growth, further enriching our strategic options and strengthening our execution capabilities. Looking ahead, we are confident in our ability to continue improving operational performance and creating long-term value for our shareholders."
First Half of Fiscal 2025 Financial Summary
- Net revenues for the six months ended June 30, 2025 were
RMB174.5 million (US ), representing a$24.4 million 16.2% increase fromRMB150.2 million in the six months ended June 30, 2024. - Gross profit increased by
16.3% fromRMB24 .3 million in the six months ended June 30, 2024, to RMB28.3 million (US .0 million) in the six months ended June 30, 2025.$4 - Gross profit margin remained stable at
16.2% in the six months ended June 30, 2024 and 2025. - Net loss was
RMB19 .9 million (US .8 million) for the six months ended June 30, 2025, compared with$2 RMB14 .0 million for the six months ended June 30, 2024. - Net loss per share, basic and diluted, was
RMB11.45 (US ) for the six months ended June 30, 2025, compared with$1.60 RMB10.58 for the six months ended June 30, 2024.
Unaudited Financial Results for the First Half of Fiscal 2025
- Net revenues for the six months ended June 30, 2025 were
RMB174.5 million (US ), representing a$24.4 million 16.2% increase fromRMB150.2 million in the six months ended June 30, 2024, which was primarily attributable to the increase in the net revenues from Internet hospital. Net revenues from Internet hospital increased by82.4% fromRMB36.8 million in the six months ended June 30, 2024 toRMB67.2 million (US ) in the six months ended June 30, 2025, primarily attributable to the increase in revenues generated from online pharmacy sales. In the first half of 2025, the Company strengthened its cooperation with pharmaceutical manufacturers to sell their products through its Internet hospital platform. As a result, revenue from the Company's online pharmacy sales increased from$9.4 million RMB36.3 million in the six months ended June 30, 2024 toRMB66.4 million (US ) in the six months ended June 30, 2025.$9.3 million - Cost of revenues increased by
16.2% fromRMB125.8 million in the six months ended June 30, 2024 toRMB146.2 million (US ) in the six months ended June 30, 2025, primarily due to the increase in cost of revenues in online pharmacy sales from$20.4 million RMB20.4 million in the six months ended June 30, 2024 toRMB40.0 million (US ) in the six months ended June 30, 2025, which was in line with the increase in the Company's net revenues from Internet hospital.$5.6 million - Gross profit increased by
16.3% fromRMB24.3 million for the six months ended June 30, 2024, toRMB28.3 million (US ) in the six months ended June 30, 2025.$4.0 million - Gross profit margin remained stable at
16.2% in the six months ended June 30, 2024 and 2025. The gross profit margin of the Company's Internet hospital decreased from44.7% in the six months ended June 30, 2024 to40.5% in the six months ended June 30, 2025, mainly due to the increase in the online pharmacy sales of products with lower gross profit margin. The gross profit margin of the Company's pharmaceutical supply chain business decreased from6.9% in the six months ended June 30, 2024 to1.1% in the six months ended June 30, 2025, which was primarily because the gross profit margin of the Company's pharmacy wholesale customers newly acquired in the six months ended June 30, 2024 was higher than that of customers in the six months ended June 30, 2025. - Sales and marketing expenses increased by
11.6% fromRMB24.9 million in the six months ended June 30, 2024 toRMB27.8 million (US ) in the six months ended June 30, 2025, primarily due to higher service fees to doctors and increased staff costs in line with the growth in revenues from Internet hospital business, partially offset by a slight decrease in advertising and promotion costs resulting from a relatively stable pharmaceutical supply chain business.$3.9 million - General and administrative expenses increased by
53.5% fromRMB6.8 million in the six months ended June 30, 2024 toRMB10.5 million (US ) in the six months ended June 30, 2025, primarily due to the increase in consultancy and professional service fees incurred in connection with the Company's initial public offering, partially offset by the decrease in expected credit loss recognized resulting from the efforts for collection of receivables.$1.5 million - Research and development expense remained relatively stable at
RMB1.5 million (US ) for the six months ended June 30, 2024 and 2025.$0.2 million - Impairment loss on long-lived assets recorded was
RMB0.02 million andRMB2.0 million (US ) for the six months ended June 30, 2024 and 2025, respectively.$0.3 million - Loss from operation was
RMB13.5 million (US ) for the six months ended June 30, 2025, compared with$1.9 million RMB8.9 million for the six months ended June 30, 2024. - Net loss was
RMB19.9 million (US ) for the six months ended June 30, 2025, compared with RMB$2.8 million RMB14.0 million for the six months ended June 30, 2024. - Net loss per share, basic and diluted, was
RMB11.45 (US ) for the six months ended June 30, 2025, compared with$1.60 RMB10.58 for the six months ended June 30, 2024.
Financial Condition
- Cash and cash equivalents of
RMB5.7 million (US ) as of June 30, 2025, compared to$0.8 million RMB7.7 million as of December 31, 2024. - Net cash used in operating activities was
RMB15.0 million (US ) for the six months ended June 30, 2025, compared with$2.1 million RMB10.6 million for the six months ended June 30, 2024. - Net cash used in investing activities was
RMB512,200 (US ) for the six months ended June 30, 2025, compared with$71,500 RMB17,862 for the six months ended June 30, 2024. - Net cash provided by financing activities was
RMB13.6 million (US ) for the six months ended June 30, 2025, compared with$1.9 million RMB16.6 million for the six months ended June 30, 2024.
Exchange Rate Information
This announcement contains translations of certain RMB amounts into
Recent Development
On October 9, 2025, the Company completed its initial public offering (the "Offering") of 5,000,004 American Depositary Shares ("ADSs") at a public offering price of
About POMDOCTOR LIMITED
POMDOCTOR LIMITED is a leading online medical services platform for chronic diseases in
Forward-Looking Statements
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's filings with the SEC.
For more information, please contact:
POMDOCTOR LIMITED
Investor Relations Department
Email: ir@7lk.com
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com
POMDOCTOR LIMITED UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||||||
December 31, | June 30, | June 30, | ||||||||||
RMB | RMB | US$ | ||||||||||
Assets | ||||||||||||
Current assets: | ||||||||||||
Cash and cash equivalents (including amounts of the consolidated VIEs of | 7,651,695 | 5,746,989 | 802,249 | |||||||||
Accounts receivable, net (including amounts of the consolidated VIEs of | 8,374,608 | 6,128,066 | 855,445 | |||||||||
Accounts receivable – a related party (including amounts of the | 424,259 | 584,802 | 81,635 | |||||||||
Amount due from related parties (including amounts of the consolidated | 5,632,987 | 7,418,671 | 1,035,607 | |||||||||
Inventories (including amounts of the consolidated VIEs of | 9,165,973 | 6,447,637 | 900,055 | |||||||||
Other receivables, net (including amounts of the consolidated VIEs of | 5,318,724 | 5,231,722 | 730,319 | |||||||||
Advances to suppliers (including amounts of the consolidated VIEs of | 929,167 | 2,921,966 | 407,891 | |||||||||
Total current assets | 37,497,413 | 34,479,853 | 4,813,201 | |||||||||
Non-current assets: | ||||||||||||
Property and equipment, net (including amounts of the consolidated VIEs | 461,362 | 394,107 | 55,015 | |||||||||
Other non-current assets (including amounts of the consolidated VIEs of | 831,132 | 1,307,832 | 182,566 | |||||||||
Deferred offering costs (including amounts of the consolidated VIEs of | 7,437,679 | 7,690,157 | 1,073,505 | |||||||||
Total non-current assets | 8,730,173 | 9,392,096 | 1,311,086 | |||||||||
Total assets | 46,227,586 | 43,871,949 | 6,124,287 | |||||||||
POMDOCTOR LIMITED UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS — (Continued) | ||||||||||||
December 31, | June 30, | June 30, | ||||||||||
RMB | RMB | US$ | ||||||||||
Liabilities | ||||||||||||
Current liabilities: | ||||||||||||
Accounts payable (including amounts of the consolidated VIEs of | 25,320,486 | 25,164,804 | 3,512,871 | |||||||||
Accounts payable – a related party (including amounts of the consolidated | 25,891 | 13,711 | 1,914 | |||||||||
Short-term bank loans (including amounts of the consolidated VIEs of | 34,958,333 | 34,708,333 | 4,845,096 | |||||||||
Long-term bank loans, current (including amounts of the consolidated | 300,000 | 2,400,000 | 335,027 | |||||||||
Long-term loans, current (including amounts of the consolidated VIEs of | 10,000,000 | 10,000,000 | 1,395,946 | |||||||||
Long-term loans from third parties, current (including amounts of the | 2,320,082 | 2,295,082 | 320,381 | |||||||||
Salary and welfare payable (including amounts of the consolidated VIEs | 15,375,537 | 15,543,259 | 2,169,755 | |||||||||
Advance from customers (including amounts of the consolidated VIEs of | 1,756,046 | 942,724 | 131,599 | |||||||||
Value added tax ("VAT") and other tax payable (including amounts of the | 815,462 | 998,295 | 139,357 | |||||||||
Other payables (including amounts of the consolidated VIEs of | 12,888,750 | 10,543,438 | 1,471,806 | |||||||||
Accrued liabilities (including amounts of the consolidated VIEs of | 9,712,966 | 11,564,144 | 1,614,292 | |||||||||
Short-term loans from third parties (including amounts of the consolidated | 11,551,614 | 7,194,342 | 1,004,291 | |||||||||
Loans from related parties, current (including amounts of the consolidated | 13,821,875 | 33,194,670 | 4,633,797 | |||||||||
Amount due to related parties (including amounts of the consolidated | 36,829,010 | 42,403,073 | 5,919,241 | |||||||||
POMDOCTOR LIMITED UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS — (Continued) | ||||||||||||
December 31, | June 30, | June 30, | ||||||||||
RMB | RMB | US$ | ||||||||||
Operating lease liabilities, current (including amounts of the | 1,388,863 | 1,790,319 | 249,919 | |||||||||
Other current liabilities (including amounts of the consolidated | 2,080,556 | 237,580 | 33,165 | |||||||||
Total current liabilities | 179,145,471 | 198,993,774 | 27,778,457 | |||||||||
Long-term bank loans, noncurrent (including amounts of the | 8,400,000 | 5,700,000 | 795,689 | |||||||||
Loans from related parties, noncurrent (including amounts of the | 356,690,859 | 356,390,859 | 49,750,246 | |||||||||
Operating lease liabilities, noncurrent (including amounts of the | 1,672,218 | 2,346,664 | 327,582 | |||||||||
Total non-current liabilities | 366,763,077 | 364,437,523 | 50,873,517 | |||||||||
Total liabilities | 545,908,548 | 563,431,297 | 78,651,974 | |||||||||
Commitments and contingencies | — | — | — | |||||||||
Mezzanine equity | ||||||||||||
Convertible redeemable preferred shares ( | 1,595,051,558 | 1,642,498,390 | 229,283,934 | |||||||||
Redeemable non-controlling interests | 168,671,234 | 173,630,137 | 24,237,833 | |||||||||
Total mezzanine equity | 1,763,722,792 | 1,816,128,527 | 253,521,767 | |||||||||
Equity (deficit) | ||||||||||||
Class A ordinary shares ( | 2,988 | 2,988 | 417 | |||||||||
Class B Ordinary shares ( | 1,408 | 1,408 | 197 | |||||||||
Subscription receivable | (1,608) | (1,608) | (224) | |||||||||
Accumulated deficit | (2,263,419,477) | (2,335,709,744) | (326,052,508) | |||||||||
Accumulated other comprehensive (loss) income | (5,231) | 1,875 | 262 | |||||||||
Total Pomdoctor Limited's shareholders' deficit | (2,263,421,920) | (2,335,705,081) | (326,051,856) | |||||||||
Noncontrolling interests | 18,166 | 17,206 | 2,402 | |||||||||
Total deficit | (2,263,403,754) | (2,335,687,875) | (326,049,454) | |||||||||
Total liabilities, mezzanine equity and deficit | 46,227,586 | 43,871,949 | 6,124,287 | |||||||||
POMDOCTOR LIMITED UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | ||||||||||||
For Six Months Ended June 30, | ||||||||||||
2024 | 2025 | 2025 | ||||||||||
RMB | RMB | US$ | ||||||||||
Net revenues – third parties | 149,266,587 | 174,283,295 | 24,329,010 | |||||||||
Net revenues – a related party | 897,822 | 186,556 | 26,042 | |||||||||
Net revenues | 150,164,409 | 174,469,851 | 24,355,052 | |||||||||
Cost of revenues | 125,823,734 | 146,152,450 | 20,402,095 | |||||||||
Gross profit | 24,340,675 | 28,317,401 | 3,952,957 | |||||||||
Operating expenses: | ||||||||||||
Sales and marketing expenses | 24,884,898 | 27,761,736 | 3,875,389 | |||||||||
General and administrative expenses | 6,835,897 | 10,494,487 | 1,464,974 | |||||||||
Research and development expenses | 1,507,847 | 1,479,909 | 206,587 | |||||||||
Impairment loss on long-lived assets | 17,861 | 2,041,299 | 284,954 | |||||||||
Total operating expenses | 33,246,503 | 41,777,431 | 5,831,904 | |||||||||
Loss from operations | (8,905,828) | (13,460,030) | (1,878,947) | |||||||||
Other income (expenses): | ||||||||||||
Other income | 1,078,270 | 28,027 | 3,912 | |||||||||
Other expense | (33,681) | (130,291) | (18,188) | |||||||||
Interest expense | (6,179,172) | (6,471,198) | (903,344) | |||||||||
Government grants | 13,858 | 148,000 | 20,660 | |||||||||
Total other expense, net | (5,120,725) | (6,425,462) | (896,960) | |||||||||
Loss before income tax | (14,026,553) | (19,885,492) | (2,775,907) | |||||||||
Income tax expense | — | — | — | |||||||||
Net loss | (14,026,553) | (19,885,492) | (2,775,907) | |||||||||
Accretion to redemption value of mezzanine equity | (52,695,272) | (52,405,735) | (7,315,559) | |||||||||
Less: Net income (loss) attributable to noncontrolling interests | 27,639 | (960) | (134) | |||||||||
Net loss attributable to the Pomdoctor Limited's ordinary | (66,749,464) | (72,290,267) | (10,091,332) | |||||||||
Net loss | (14,026,553) | (19,885,492) | (2,775,907) | |||||||||
Other comprehensive (loss) income: | ||||||||||||
Total other comprehensive (loss) income | (3,970) | 7,106 | 992 | |||||||||
Total comprehensive loss | (14,030,523) | (19,878,386) | (2,774,915) | |||||||||
Accretion to redemption value of mezzanine equity | (52,695,272) | (52,405,735) | (7,315,559) | |||||||||
Less: comprehensive income (loss) attributable to noncontrolling | 27,639 | (960) | (134) | |||||||||
Comprehensive loss attributable to the Pomdoctor Limited's | (66,753,434) | (72,283,161) | (10,090,340) | |||||||||
Loss per share | ||||||||||||
Basic and diluted | (10.58) | (11.45) | (1.60) | |||||||||
Weighted average number of ordinary shares outstanding* | ||||||||||||
Basic and diluted | 6,310,198 | 6,310,198 | 6,310,198 | |||||||||
* Ordinary shares and share data have been retroactively restated to give effect to the nominal share issuance for | ||||||||||||
POMDOCTOR LIMITED UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||||||
For Six Months Ended June 30, | ||||||||||||
2024 | 2025 | 2025 | ||||||||||
RMB | RMB | US$ | ||||||||||
Net cash used in operating activities | (10,631,121) | (14,987,658) | (2,092,195) | |||||||||
Cash flows from investing activities: | ||||||||||||
Payment for purchase of property and equipment | (17,862) | (2,200) | (307) | |||||||||
Payment for long-term investment | — | (510,000) | (71,193) | |||||||||
Net cash used in investing activities | (17,862) | (512,200) | (71,500) | |||||||||
Cash flows from financing activities: | ||||||||||||
Loans from related parties | 11,219,986 | 24,750,310 | 3,455,010 | |||||||||
Repayment to related parties | (14,436,941) | (5,677,514) | (792,550) | |||||||||
Proceeds from short-term bank loans | 37,000,000 | 29,000,000 | 4,048,244 | |||||||||
Repayment of short-term bank loans | (19,300,000) | (29,250,000) | (4,083,143) | |||||||||
Repayment of long-term bank loans | (54,628) | (600,000) | (83,757) | |||||||||
Loans from third parties | 8,759,366 | 1,600,000 | 223,351 | |||||||||
Repayment to third parties | (4,968,912) | (5,982,272) | (835,093) | |||||||||
Payment for deferred offering cost | (1,656,745) | (252,478) | (35,245) | |||||||||
Net cash provided by financing activities | 16,562,126 | 13,588,046 | 1,896,817 | |||||||||
Effect of exchange rate changes | (3,970) | 7,106 | 992 | |||||||||
Net increase (decrease) in cash and cash equivalents and restricted | 5,909,173 | (1,904,706) | (265,886) | |||||||||
Cash and cash equivalents and restricted cash at beginning of the | 6,805,099 | 7,651,695 | 1,068,135 | |||||||||
POMDOCTOR LIMITED UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS — (Continued) | ||||||||||||
For Six Months Ended June 30, | ||||||||||||
2024 | 2025 | 2025 | ||||||||||
RMB | RMB | US$ | ||||||||||
Including: | ||||||||||||
Cash and cash equivalents at beginning of the period | 6,717,031 | 7,651,695 | 1,068,135 | |||||||||
Restricted cash at beginning of the period | 88,068 | — | — | |||||||||
Cash and cash equivalents and restricted cash at end of the period | 12,714,272 | 5,746,989 | 802,249 | |||||||||
Including: | ||||||||||||
Cash and cash equivalents at end of the period | 12,714,272 | 5,746,989 | 802,249 | |||||||||
Supplemental disclosures of cash flows information: | ||||||||||||
Cash paid for interest expense | 1,130,609 | 2,382,125 | 332,532 | |||||||||
Supplemental disclosure of noncash investing and financing activities: | ||||||||||||
Operating lease right-of-use assets obtained in exchange for new operating | — | 2,039,099 | 284,647 | |||||||||
View original content:https://www.prnewswire.com/news-releases/pomdoctor-limited-announces-first-half-of-fiscal-2025-unaudited-financial-results-302632067.html
SOURCE POMDOCTOR LIMITED
FAQ
What were Pomdoctor (POM) net revenues for H1 fiscal 2025?
How much did Pomdoctor's online pharmacy sales grow in H1 2025 (POM)?
What was Pomdoctor's (POM) net loss and EPS in H1 2025?
How strong is Pomdoctor's cash position after H1 2025?
How did Pomdoctor (POM) finance operations after H1 2025?
Did Pomdoctor (POM) maintain gross margins in H1 2025?
